GlassScriptPhysician profile
Adeeba S Khan
NPI 1205397908
$2,716.80
in general payments reported to CMS, 2019-2025
33 companies · $2,441 in 2025
The $2,441 reported for 2025 was more than what 76% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $276 · 2025: $2,441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,716.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $490.27 | 2024-2025 | |
| Ucb, INC. | $254.85 | 2024-2025 | Fintepla, Nayzilam, Rystiggo |
| Janssen Biotech, INC. | $184.19 | 2025 | |
| Acadia Pharmaceuticals INC | $162.73 | 2024-2025 | Nuplazid, Daybue |
| Genentech USA, INC. | $158.67 | 2025 | Ocrevus Zunovo, Ocrevus |
| Axsome Therapeutics, INC. | $146.21 | 2025 | Symbravo |
| Celgene Corporation | $135.84 | 2025 | Zeposia |
| Ge Healthcare | $115.66 | 2025 | |
| Biogen, INC. | $91.09 | 2024-2025 | Tysabri, Vumerity, Skyclarys |
| Argenx US, INC. | $90.30 | 2025 | Vyvgart Hytrulo |
| Tg Therapeutics, INC. | $88.74 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $84.69 | 2025 | Dysport |
| Novartis Pharmaceuticals Corporation | $82.73 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $61.47 | 2025 | |
| Livanova USA, INC. | $58.39 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz Pharmaceuticals, LLC | $53.25 | 2024-2025 | Xeomin |
| Pfizer INC. | $50.44 | 2025 | |
| Csl Behring | $45.12 | 2025 | Hizentra, Privigen |
| Lilly USA, LLC | $41.34 | 2024-2025 | Emgality, Kisunla |
| Teva Pharmaceuticals USA, INC. | $37.74 | 2025 | Austedo Xr |
| Azurity Pharmaceuticals, INC. | $33.55 | 2024-2025 | Horizant |
| Genzyme Corporation | $31.16 | 2025 | |
| Octapharma USA, INC. | $26.50 | 2024 | Octagam Immune Globulin (Human) |
| Neurelis, INC. | $25.39 | 2025 | Valtoco |
| Amneal Pharmaceuticals LLC | $22.76 | 2025 | Crexont |
| Alexion Pharmaceuticals, INC. | $22.10 | 2025 | Ultomiris |
| Catalyst Pharmaceuticals, INC. | $20.60 | 2025 | |
| Kyowa Kirin, INC. | $19.70 | 2025 | |
| Merck Sharp & Dohme LLC | $18.26 | 2024 | Vaxneuvance, Vaxelis, Rotateq |
| Globus Medical, INC. | $17.73 | 2025 | Senza |
| Tanabe Pharma America, INC. | $17.49 | 2025 | Radicava |
| Tonix Medicines, INC. | $13.98 | 2025 | Tonmya |
| Takeda Pharmaceuticals U.S.A., INC. | $13.86 | 2025 | Hyqvia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adeeba Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.